The report provides a detailed analysis essential for establishing a pentamidine production plant. It encompasses all critical aspects necessary for pentamidine production, including the cost of pentamidine production, pentamidine plant cost, pentamidine production costs, and the overall pentamidine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a pentamidine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Pentamidine is an antimicrobial medication that is used to treat protozoal and fungal infections. It is mainly utilised in immunocompromised patients. It is administered via injection for active Pneumocystis jirovecii pneumonia (PCP or PJP), a serious opportunistic infection in individuals with HIV/AIDS, cancer, or transplants.
It is taken by inhalation for prevention in those with low CD4 counts. It is also utilised as a second-line treatment for early-stage African trypanosomiasis (sleeping sickness caused by Trypanosoma brucei gambiense) and visceral and cutaneous leishmaniasis. It is also used in rarer infections like Balamuthia, babesiosis, Giardia, or Cryptosporidium. Its common side effects include respiratory irritation (throat and chest pain, cough, wheezing), nausea and vomiting, low blood pressure and sugar, abnormal liver tests, etc.
The market for pentamidine is driven by the growing cases of HIV/AIDS and other immunocompromising conditions. Its utilisation in endemic tropical diseases like African trypanosomiasis (sleeping sickness) and leishmaniasis sustains demand in low-income countries. The presence of limited alternative therapies makes it useful as a second-line option amid ongoing public health initiatives. Its usage as an antifungal application and potential in rare infections like babesiosis further support its market.
The industrial pentamidine procurement is affected by elevated production costs because of the complex diamidine synthesis process. The demand for specialised chemical intermediates and GMP-compliant facilities affects its availability. Other factors, like regulatory hurdles for orphan drug designations and strict pharmacovigilance requirements for injectable formulations, increase compliance costs.
Raw Material for Pentamidine Production
According to the pentamidine production plant project report, the key raw materials used in the production of pentamidine include 4-cyanophenol, 1,5-dibromopentane, methanol, ammonia, and isethionic acid.
Production Process of Pentamidine
The extensive pentamidine production cost report consists of the following major industrial production process:
- From 4-cyanophenol: The production process of pentamidine involves a two-step process from 4-cyanophenol. First, 4-cyanophenol goes through Williamson ether synthesis with 1,5-dibromopentane to form the bis(4-cyanophenyl) pentyl ether linker. This is followed by the Pinner reaction on the nitrile groups using HCl and methanol to generate bis-imidates. Then ammonolysis with methanolic ammonia to yield the bis-amidine product. The free base is converted to pentamidine isethionate salt by reaction with isethionic acid.
Pentamidine free base has the molecular formula of C19H24N4O2 and a molecular weight of 340.4 g/mol. It is an odourless white or almost white crystalline powder with a very bitter taste and a slight butyric odour in certain forms. It is hygroscopic, sensitive to prolonged air exposure, and tends to precipitate when reconstituted with sodium chloride solutions. It has a melting point in the range 186–194 degree Celsius and shows high water solubility. It maintains a pH of 4.5–6.5 in 5% aqueous solution and displays moderate lipophilicity per LogP values. Its isethionate salt form has the molecular formula of C23H36N4O10S2 and a molecular weight of 592.75 g/mol. It is a lyophilised white powder that is non-flammable, featuring collision cross-sections of approximately 176.9–183.2 Ų. It has a polar surface area of 118.2 Ų with 6 hydrogen bond acceptors and donors, 14 rotatable bonds, 2 rings, and low oral bioavailability.